Sino Biopharmaceutical's (HKG:1177) Tulobuterol Patches obtained marketing approval from the National Medical Products Administration of China, a Friday bourse filing said.
The approval covers the usage of the patches for the relief of symptoms of obstructive airway diseases including dyspnoea caused by bronchial asthma, acute bronchitis, chronic bronchitis, and emphysema.
Compared to other traditional treatments, tulobuterol patch controls asthma symptoms more effectively and is a more convenient and safer solution for the long-term treatment of patients with obstructive airway diseases.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。